COTHERIX PULMONARY ARTERIAL HYPERTENSION DRUG APPROVED

The FDA has granted approval to Ventavis, an inhalation solution for treating pulmonary arterial hypertension (PAH).

Ventavis is marketed in the U.S. by CoTherix and in Europe and Australia by Schering AG. The drug has been approved to treat PAH in patients with NYHA Class III or IV symptoms.